Navigation Links
Bioniche Pharma Launches Enlon(R) and Enlon-Plus(R) Injection
Date:5/14/2009

LAKE FOREST, Ill., May 14 /PRNewswire/ -- - Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, announced the launch of Enlon(R) (edrophonium chloride injection, USP) and Enlon-Plus(R) (edrophonium chloride, USP and atropine sulfate, USP) Injection.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080702/AQW070LOGO)

"The acquisition and launch of Enlon(R) represent Bioniche's continued growth and a commitment to bringing this important therapy back to market and into the hands of health care professionals," said Steve Thornton, CEO, Bioniche Pharma.

Bioniche purchased the rights and certain assets related to the Enlon(R) product line from Baxter Corporation, which discontinued Enlon(R) in February 2008. According to IMS data, 2007 sales of Enlon(R) and Enlon-Plus(R) totaled $2,727,000 and 307,000 units.

Bioniche will supply Enlon(R) in 10 mg/mL, 15 mL vials and Enlon-Plus(R) in 15 mL vials, in addition to the currently available 5 mL ampul of Enlon-Plus(R).

About Bioniche Pharma:

Bioniche Pharma is a global manufacturer of injectable pharmaceutical products serving a variety of niche markets, with expertise in injectable hyaluronic acid products for use in orthopedics, rheumatology, urology and dermatology. The company's growth is fueled by an internal development pipeline and an aggressive acquisition strategy for products. Bioniche Pharma was acquired in February 2006 by RoundTable Healthcare Partners, a private equity firm based in Lake Forest, Illinois. More information about Bioniche Pharma can be found at www.bionichepharma.com.


'/>"/>
SOURCE Bioniche Pharma
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1

Related biology technology :

1. Bioniche Reports Fiscal 2007 Year-End Results
2. Bioniche Pharma Acquires Baxters ENLON(R) and ENLON-PLUS(R)
3. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
4. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
5. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
8. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
9. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2009)... Dec. 10 Dendreon Corporation (Nasdaq: DNDN ... public offering of 15,000,000 shares of its common stock ... share. Dendreon also granted to the underwriters a ... shares of common stock to cover overallotments, if any. ... 15, 2009, subject to customary closing conditions. ,, J. ...
(Date:12/10/2009)... the National Institutes of Health (NIH), awarded a $2.18 million ... a non-invasive, passive diffusion-based treatment for severe, non-infectious uveitis. ... ... UT (PRWEB) December 10, 2009 -- The National Eye Institute ... awarded a $2.18 million grant to Aciont Inc. to help ...
(Date:12/10/2009)... BioSciences Inc. (NYSE Amex: YMI ; TSX: ... identifies and advances a diverse portfolio of promising ... provided an update on the proposed transaction which ... into YM, details of which were announced on ... Cytopia has unanimously recommended that its shareholders vote ...
(Date:12/10/2009)... CORALVILLE, Iowa, Dec. 10 Vivakor, ... that it has entered into an exclusive, ... specialist, Regeneca International, Inc. ( www.regeneca.com ). ... distribution rights to a new cutting-edge nutraceutical ... the development of future formulations by Vivakor ...
Breaking Biology Technology:Dendreon Announces Pricing of Common Stock Offering 2Dendreon Announces Pricing of Common Stock Offering 3NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont 2NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont 3YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 2YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 3YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 4Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 2Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 3
... RiverVest Venture Partners,announced today that it has completed ... L.P., with total committed capital of $75,million from ... a Small Business Investment Company, had total private ... from the Small Business Administration., RiverVest co-founder ...
... Jersey, April 11, Rosetta Genomics Ltd. (Nasdaq: ROSG ... and therapeutics, announced,today it will present multiple posters ... The posters will include data on Rosetta Genomics,unique ... to develop,objective and standardized diagnostic tests and therapeutics ...
... 11, 2008 In the event of an outbreak ... changes responsible for virulence or drug resistance is essential ... and analysis of a pathogen genome is time-intensive and ... now developed a comparative genomics strategy to drastically reduce ...
Other Biology Technology:RiverVest Venture Partners(R), a St. Louis-Based Venture Capital Firm Focusing on Life Sciences, Closes on Fund II, Names John P. McKearn, Ph.D., Venture Partner 2RiverVest Venture Partners(R), a St. Louis-Based Venture Capital Firm Focusing on Life Sciences, Closes on Fund II, Names John P. McKearn, Ph.D., Venture Partner 3Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference 2Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference 3Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference 4Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference 5Scientists develop strategy to rapidly describe outbreak strains with next-generation DNA sequencing 2
(Date:12/14/2009)... -- MODA Technology Partners, a global software company ... testing for the Pharmaceutical industry, today announced the ... generation mobile data acquisition platform. The latest release ... their regulated manufacturing processes. ,, MODA 3.0 ... Fully-Configurable Test Methods: Each test method in ...
(Date:12/13/2009)... have resolved a question about how a popular ... using biosensors that reveal previously hidden components of ... delusions and hallucinations characterize the illness, people with ... information in a particular order, difficulties that interfere ... function well, said Lee Schroeder, a student in ...
(Date:12/13/2009)... 2009Researchers at The Scripps Research Institute have solved ... from an ancient family of enzymes can have ... addition to providing guidance for understanding other molecules ... underpinning for the protein,s possible use for combating ... research was published in the December 13, 2009 ...
Breaking Biology News(10 mins):MODA Announces Availability of Third Generation Mobile Data Acquisition Platform 2New biosensors reveal workings of anti-psychotic drugs in the living brain 2Scripps Research scientists crack mystery of protein's dual function 2Scripps Research scientists crack mystery of protein's dual function 3Access Pharmaceuticals to Present at the Rodman 26 Renshaw Annual Healthcare Conference 13766 1Access Pharmaceuticals to Present at the Rodman 26 Renshaw Annual Healthcare Conference 13766 2Access Pharmaceuticals to Present at the Rodman 26 Renshaw Annual Healthcare Conference 13766 3LIVALO 28R 29 Demonstrates Sustained Long Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 55843 1LIVALO 28R 29 Demonstrates Sustained Long Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 55843 2LIVALO 28R 29 Demonstrates Sustained Long Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 55843 3LIVALO 28R 29 Demonstrates Sustained Long Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 55843 4LIVALO 28R 29 Demonstrates Sustained Long Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 55843 5Thoratec Presentation at Baird Conference to be Webcast 13764 1
... is the shape of the cochlea the snail-shell-shaped organ ... impulses that the brain deciphers which proves to be ... the Proceedings of the National Academy of Sciences establishes a ... limit of more than a dozen different mammals. , The ...
... of patients around the world following a routine dosage ... a frantic search to uncover what could make the ... Institute was among a small group of scientists with ... the source of the contamination. , Robert J. ...
... May Enable Food-Borne Pathogens on Leafy Vegetables ... sequester harmful food-borne pathogens ultimately contributing to their ... Technological University, Cookeville and the Produce Safety and ... their findings in the April 2008 issue of ...
Other Biology News:Study links low-frequency hearing to shape of the cochlea 2Study links low-frequency hearing to shape of the cochlea 3Study links low-frequency hearing to shape of the cochlea 4Deadly dose: Rensselaer heparin expert helps uncover source of lethal contamination 2Tips from the Journals of the American Society for Microbiology 2Tips from the Journals of the American Society for Microbiology 3Tips from the Journals of the American Society for Microbiology 4
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. ID clarifier: ...
... automates the denaturation and hybridization steps in ... for clinical and research personnel. The low ... sample types, is easy to use, and ... while ensuring overall precision and accuracy in ...
Extremely high efficiency packaging extracts useful for transfecting our EpiFOS™ or CopyControl™ Fosmids, or any DNA vector with cos sites. A tremendous value when conpared to the competition...
... Iodide (PI) is a fluorescent nucleic acid ... acids. As a nuclear counterstain, propidium ... red in color. The fluorescent red ... blue fluorochromes such as FITC, Cy2 or ...
Biology Products: